market uncertainty
source: by Timothy Hay When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes. But it was more of […]
Read MoreSeptember 28, 2011 source: Wall Street Journal All good things, unfortunately, come to an end. The last year or two have been spectacular for entrepreneurs. Investor enthusiasm has been intense, meaning that start-ups had the upper hand and could get financing at extraordinarily generous terms. But I’m afraid that the curtain is about to fall. […]
Read MoreSeptember 23, 2011 source: Forbes What the Solyndra Bankruptcy Means for Cleantech Investors by Jennifer Kho. Forbes Contributor As executives of defunct solar-panel manufacturer Solyndra keep mum in Washington, Silicon Valley and Wall Street are discussing what the bankruptcy – and the federal investigation – could mean for investors. “It has an impact; it’s such a […]
Read MoreSeptember 15, 2011 source: Xconomy For a while, I was optimistic that 2011 would be a good year for venture capital-backed IPOs, and it wasn’t just wishful thinking. There were 72 VC-backed IPOs last year—six times as many as in 2009. The year ended with a bang and 2011 got off to a good start. […]
Read MoreSeptember 1, 2010 source: xconomy Brad Webb, Venture Partner at Claremont Creek Ventures, was featured today on the xcononomy website discussing the implications for venture investment of the recent judicial ruling regarding federal funding for stem cell research. Last week’s federal district court ruling ordering an immediate halt in federal funding for stem cell research […]
Read MoreMeet our team
Claremont Creek Ventures was founded in 2005 by Nat Goldhaber, John Steuart and Randy Hawks to pursue early stage investing in exceptional technology startups.
NAT GOLDHABER
Nat Goldhaber is a co-founder of Claremont Creek Ventures.
BRAD WEBB
Brad is focused on the role of genomics and biomarker data analytics in driving the next generation of diagnostics and drug development.
RANDY HAWKS
Randy Hawks is a co-founder of Claremont Creek Ventures.